FOR IMMEDIATE RELEASE
Norwich Pharmaceuticals Introduces Clinical Services Division
Norwich Clinical Services to offer complete CRO expertise, pharmacovigilance capabilities
Norwich, New York – April 28, 2010 – Norwich Pharmaceuticals, Inc. (Norwich), a leader in full-
service contract development and manufacturing, today announced the formation of Norwich Clinical
Services to provide clinical testing capabilities that will further expand the company’s third party
services. Norwich Clinical Services will offer a complete range of clinical research capabilities
including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services.
“The introduction of Norwich Clinical Services underscores our strategic focus to provide customers
with a comprehensive solution for all stages of product life cycle management,” said Doug Drysdale,
chief executive officer of Alvogen, a company that includes Norwich Pharmaceuticals and Norwich
Clinical Services. “We have assembled the highest level of professional expertise to ensure Norwich
Clinical Services matches our tradition of unparalleled quality standards and delivers contract
pharmaceutical services with everyday excellence.”
Dr. Saral Thangam, MD, PhD, managing director of Norwich Clinical Services, will lead an experienced
team of professionals who each have at least 15 years experience in clinical research and life sciences.
Dr. Thangam completed her medical training with an Internal Medicine specialization at Christian
Medical College, Vellore, and her PhD in physiology was earned at St. John’s Medical College,
Bangalore. Prior to joining Norwich, Dr. Thangam was the managing director of Lotus Labs.
“The Norwich reputation is well known and respected throughout the contract pharmaceutical industry
for its focus on quality and customer service, and Norwich Clinical Services will meet and support that
benchmark with professionalism, efficiency and stringent adherence to GCP, GLP, CFR part 11 and